Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01266317
Other study ID # PRO10110151
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received December 22, 2010
Last updated February 14, 2018
Start date March 2011
Est. completion date July 2015

Study information

Verified date February 2018
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label Phase I/II trial to assess the feasibility and safety of combined plasma exchange (PEX), rituximab, and conventional corticosteroid administration on the outcome of hospitalized patients with acute IPF exacerbations. The specific aims of this study are:

1. To assess the feasibility and safety of combined PEX, rituximab, and conventional corticosteroid administrations for the treatment of hospitalized patients with acute IPF exacerbations by monitoring indices of respiratory (PaO2) and cardiovascular function during the treatment interval.

2. To assess the efficacy of combined PEX, rituximab, and conventional corticosteroid administrations for the treatment of hospitalized patients with acute IPF exacerbations on patient survival in comparison to historical controls. Patient survival for this investigation will be defined using the composite outcome of 60 day survival and/or survival to lung transplantation.

Subjects between 18 and 80 years of age who have a confirmed diagnosis of IPF, and meet all the study requirements will be enrolled in this study. A total of 10 subjects of both genders and all ethnic backgrounds with acute IPF exacerbations hospitalized at University of Pittsburgh Medical Center will be enrolled in this study.


Description:

This is a prospective, open-label Phase II, non-randomized clinical trial to assess the feasibility and safety of combined plasma exchange (PEX), rituximab, and conventional corticosteroid administration in patients with acute IPF exacerbations.

INCLUSION CRITERIA:

1. A diagnosis of idiopathic pulmonary fibrosis that fulfills American Thoracic Society Consensus Criteria.

2. Unexplained worsening or development of dyspnea or hypoxemia within 30 days leading to the current hospitalization.

3. Radiographic imaging showing ground-glass abnormality and/or consolidation superimposed on a background of reticular or honeycomb pattern consistent with UIP.

4. Intent on the part of the treating physician to use high dose steroid therapy as a therapeutic effort to treat a diagnosis of acute IPF exacerbation.

EXCLUSION CRITERIA

1. Diagnosis of documented infection based upon clinical evaluation and microbial testing.

2. Diagnosis of thromboembolic disease by clinical assessment.

3. Diagnosis of an additional etiology for ALI/ARDS based upon clinical assessment to include sepsis, aspiration, trauma, inhalational injury, acute pancreatitis, drug toxicity, blood product transfusion reaction, or stem cell transplantation.

4. Diagnosis of congestive heart failure that accounts for the hypoxemia.

5. Presence of active hepatitis B infection.

6. Coagulopathy defined as an INR > 1.8, PTT > 2 x control, and platelet count < 50K.

7. Hyperosmolar state or diabetic ketoacidosis to suggest uncontrolled diabetes mellitus or uncontrolled hypertension (systolic BP > 160 mm Hg and diastolic BP > 100 mm Hg) which would contraindicated the use of corticosteroids.

8. Hemodynamic instability defined as a vasopressor requirement which would contraindicate the use of plasmapheresis.

9. History of reaction to blood products, murine-derived products, or prior exposures to human-murine chimeric antibodies,

10. History of malignancy.

11. Inability or unwillingness to accept a blood transfusion.

12. Inability or unwillingness to complete post- treatment surveillance for 60 days.

13. Diagnosis of major comorbidities expected to interfere with subjects study participation for 60 days.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- A diagnosis of idiopathic pulmonary fibrosis that fulfills American Thoracic Society Consensus Criteria.

- Unexplained worsening or development of dyspnea or hypoxemia within 30 days leading to the current hospitalization.

- Radiographic imaging showing ground-glass abnormality and/or consolidation superimposed on a background of reticular or honeycomb pattern consistent with usual interstitial pneumonia.

- Intent on the part of the treating physician to use high dose steroid therapy as a therapeutic effort to treat a diagnosis of acute IPF exacerbation.

Exclusion Criteria:

- Diagnosis of documented infection based upon clinical evaluation and microbial testing.

- Diagnosis of thromboembolic disease by clinical assessment.

- Diagnosis of an additional etiology for Acute Lung Injury/Acute Respiratory Distress Syndrome based upon clinical assessment to include sepsis, aspiration, trauma, inhalational injury, acute pancreatitis, drug toxicity, blood product transfusion reaction, or stem cell transplantation.

- Diagnosis of congestive heart failure that accounts for the hypoxemia.

- Presence of active hepatitis B infection.

- Coagulopathy defined as an International Normalized Ratio > 1.8, Partial Thromboplastin Time > 2 x control, and platelet count < 50,000.

- Hyperosmolar state or diabetic ketoacidosis to suggest uncontrolled diabetes mellitus or uncontrolled hypertension (systolic BP > 160 mm Hg and diastolic BP > 100 mm Hg) which would contraindicated the use of corticosteroids.

- Hemodynamic instability defined as a vasopressor requirement which would contraindicate the use of plasmapheresis.

- History of reaction to blood products, murine-derived products, or prior exposures to human-murine chimeric antibodies,

- History of malignancy.

- Inability or unwillingness to accept a blood transfusion.

- Inability or unwillingness to complete post- treatment surveillance for 60 days.

- Diagnosis of major comorbidities expected to interfere with subjects study participation for 60 days.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab

Locations

Country Name City State
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Michael Donahoe

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Respiratory and/or Hemodynamic Deteriorations To assess the feasibility and safety of combined PEX, rituximab, and conventional corticosteroid administrations for the treatment of hospitalized patients with acute IPF exacerbations by monitoring indices of respiratory (PaO2) and cardiovascular function during the treatment interval. Respiratory deterioration was defined by a compilations of respiratory deteriorations (deteriorating gas exchange) and hemodynamic deteriorations (defined as a need for medical intervention). 28 days
Secondary Number of Participants Survived to 60 Days or to Transplantation The secondary outcome measures a composite outcome defined as survival to 60 days or survival to transplantation at any time post therapy. 60 days
See also
  Status Clinical Trial Phase
Recruiting NCT05570058 - Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Recruiting NCT05895565 - A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects Phase 1
Completed NCT03211507 - Idiopathic Pulmonary Fibrosis Job Exposures Study
Completed NCT02503657 - Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Recruiting NCT03873298 - Inhaled NO in IPF and COPD During 6 Minute Walk Test Phase 2
Terminated NCT03864328 - A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF Phase 2
Completed NCT05803850 - A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058 Phase 1
Withdrawn NCT05349760 - A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT05147597 - Turkish Validity and Reliability of SGRQ-I
Completed NCT04503044 - ILAs in CT Lung Cancer Screening Population
Recruiting NCT04564183 - Advancing Prevention of Pulmonary Fibrosis
Recruiting NCT05190211 - Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis N/A
Recruiting NCT04263727 - A Study of Patients With Chronic Disease
Completed NCT05353556 - Effects of Home-based Inspiratory Muscle Training in Patients With IPF N/A
Completed NCT02976935 - Functional MR Lung Imaging Using Hyperpolarised 129Xe
Recruiting NCT05193136 - Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease
Recruiting NCT06181370 - Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF Phase 1
Not yet recruiting NCT02885961 - The Coagulation Cascade in Idiopathic Pulmonary Fibrosis N/A
Completed NCT02151435 - Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis N/A